Glaxosmithkline Share News (GSK)

Leave vote would have limited impact on FTSE, says SpreadCo analyst

(ShareCast News) - Although consensus is that the FTSE 100 will rally if voters in the UK opt to remain in the European Union on Thursday and sell off on a Leave vote, the overall impact of an exit on London stocks may be limited, said SpreadCo analyst David Morrison. "The damage to the FTSE100 as a

London midday: Financials pace gains as Footsie keeps climbing

(ShareCast News) - Stocks in London were continuing to move higher come midday on Monday, alongside the largest gain the pound in three months, with investors taking their cue from strong gains in Asia as Brexit polls showed the Remain campaign was in the lead. As of 12:03 BST, the FTSE 100 was 183.

London open: Stocks surge after latest poll results

(ShareCast News) - Stocks in London surged at the start of trading, alongside the largest gain the pound in three months, with investors taking their cue from strong gains in Asia as Brexit polls showed the Remain campaign was in the lead. As of 08:43 BST the FTSE 100 was 145.82 points or 2.42% high

GSK breathes easier after successful triple-COPD trial

(ShareCast News) - Late-stage drug trials by GlaxoSmithKline on its treatment for chronic obstructive pulmonary disease (COPD) have proved successful. European and US regulatory submission are likely to be completed the end of 2016 based on the data from this Phase III clinical test by GSK and its r

TOP NEWS: Glaxo Gets Positive Top-Line Results On COPD Treatment

Factory snag hits GSK supply, causing Danish anaesthetic shortage

LONDON, June 17 (Reuters) - Manufacturing problems at a factory in Italy have disrupted production of some GlaxoSmithKline medicines, leading to shortages of a commonly used opioid anaesthetic in Denmark. The British drugmaker said on Friday it had temporarily suspended manufacturing at its

British companies prepare for long night to possible Brexit

* Britain holds EU membership referendum on June 23 * Momentum swings in polls towards "Leave" campaign * Brexit would be expected to roil currency markets * Brexit could affect trade, economy and migration By Martinne Geller and Kate Holton LONDON, June 17 (Reuters)

GSK's Head of Vaccines to step down

(ShareCast News) - GlaxoSmithKline's head of vaccines announced his decision to retire after nearly three decades of service to the firm, including a decade as a member of the board. Dr Moncef Slaoui, Chairman, Vaccines agreed with the Board that he would step down from his post on 30 June 2017. Ph

Glaxo Vaccines Chairman Moncef Slaoui To Step Down In 2017

Directors dealings: NAIT boosts stake in EKF Diagnostics to 14.1%

(ShareCast News) - Harwood Capital, acting as investment manager on behalf of North Atlantic Smaller Companies Investment Trust PLC, picked up another large batch of shares in EKF Diagnostics. Christoper Mills, who was named to the post of non-executive chairman at the global point-of-care medical d

Glaxo's ViiV Gets Approval To Lower Weight Limit For Dolutegravir

Glaxo Says Rheumatoid Arthritis Treatment Meets Primary Endpoints

GlaxoSmithKline Presents Positive Phase III Data For Benlysta

J&J, GSK rheumatoid arthritis drug meets goals of large trial

June 7 (Reuters) - An experimental drug for rheumatoid arthritis developed by Johnson & Johnson and GlaxoSmithKline slowed joint damage and improved symptoms of the disease, meeting the main goals of a large, late stage trial, according to data released on Tuesday. In the study of 1,670 pat

CORRECTED-Novartis study shows skin cancer combo also works on lungs

(Corrects paragraph one to show day of week Novartis said this was Monday, instead of Tuesday) * Novartis to seek approval after July following trial * Drug combo shrank tumours in 63 pct of patients in study * Combination already approved in skin cancer By John Miller